๐Ÿ”ฌDeep Research

AURA โ€” Aura Biosciences Inc ยท catalysts, narrative & risks

ยท18 sourcesAURA forecast โ†’

Snapshot / Context

Aura Biosciences Inc. (NASDAQ: AURA) is a US-listed, clinical-stage biopharmaceutical company in the Healthcare sector that develops a first-in-class "virus-like drug conjugate" (VDC) platform, using virus-like particles (VLPs) to target tumor cells and deliver cytotoxic payloads [1][6]. Its lead candidate, belzupacap sarotalocan, marketed as bel-sar or AU-011, is a laser-activated targeted therapy primarily aimed at choroidal melanoma, a rare, vision- and life-threatening eye cancer with no approved first-line therapies and a >50% metastasis/fatal prognosis [6][10]. Market-data as of mid-2026 showed a market cap near $627M and a stock price near $6โ€“7, though exact quotes are point-in-time [1][5].

Recent Catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’